logo

For the Inventor, By the Inventor

Nara, Japan

Sanji Hagishita

This inventor holds 11 USPTO granted patents. Top assignees: Shionogi Company Limited, Other. Active years: 1989-2003.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sanji Hagishita. Retrieved from https://idiyas.com/inventor/sanji-hagishita

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 11

% Patents Active = 100.0

Average Co-Inventor Count = 4.1

ph-index = 4

Forward Citations = 104(Granted Patents)


Location History:

  • Gose, JP (1998 - 2001)
  • Nara, JP (1989 - 2003)

Company Filing History:

goldMedal9 out of 1,001 
 
Shionogi Company Limited
 patents
silverMedal2 out of 834,659 
Other
 patents

Years Active: 1989-2003

Loading Chart...
11 patents (USPTO):Explore Patents
1. 6645976 - Indolizine SPLA2inhibitors (2003-11-11),
2. 6214876 - Indene-1-acetamide sPLA2 inhibitors (2001-04-10),
3. 5776929 - Benzodiazepine derivative (1998-07-07),
4. 5739162 - Carbamoylmethylurea derivatives (1998-04-14),
5. 5138067 - Lipid derivatives (1992-08-11),
6. 5073648 - 4-(4-alkoxyphenyl)-2-butylamine derivative and process therefor (1991-12-17),
7. 4976891 - Bicyclic sulfonamide derivatives (1990-12-11),
8. 4960909 - 7-oxabicyclo[2.2.1] heptane sulfonamide derivatives (1990-10-02),
9. 4916231 - Alkenyltetrazole derivatives (1990-04-10),
10. 4904819 - Bicyclic sulfonamide derivatives and process therefor (1990-02-27),
11. 4861913 - Bicyclic sulfonamide derivatives (1989-08-29),

Title: The Innovative Contributions of Sanji Hagishita

Introduction

Sanji Hagishita is a prominent inventor based in Nara, Japan. He has made significant contributions to the field of medicinal chemistry, particularly in the development of novel compounds for therapeutic applications. With a total of 11 patents to his name, his work has garnered attention in the scientific community.

Latest Patents

Hagishita's latest patents include a class of novel indolizine-1-functional and indolizine-3-functional compounds. These compounds are designed to inhibit sPLA-mediated release of fatty acids, which can be crucial in treating conditions such as septic shock. The specific compounds he has developed include indolizine-1-acetamides, indolizine-1-acetic acid hydrazides, indolizine-1-glyoxylamides, indolizine-3-acetamides, indolizine-3-acetic acid hydrazides, and indolizine-3-glyoxylasides. Additionally, he has worked on indene-1-acetamide compounds that serve as sPLA2 inhibitors.

Career Highlights

Throughout his career, Sanji Hagishita has been associated with Shionogi & Company Limited, where he has contributed to various research initiatives. His innovative approach to drug development has positioned him as a key figure in his field.

Collaborations

Hagishita has collaborated with notable colleagues, including Kaoru Seno and Susumu Kamata. These partnerships have further enhanced the impact of his research and innovations.

Conclusion

Sanji Hagishita's work exemplifies the spirit of innovation in medicinal chemistry. His contributions through patents and collaborations continue to influence the development of new therapeutic agents.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…